We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

9 hedge funds and large institutions have $1.28M invested in Plus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more capital invested

Capital invested by funds: $941K → $1.28M (+$338K)

0.1% less ownership

Funds ownership: 0.13% → 0.04% (-0.1%)

18% less funds holding

Funds holding: 11 → 9 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$295K
2
SM
Sabby Management
Florida
+$294K
3
Renaissance Technologies
Renaissance Technologies
New York
+$124K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$70.5K
5
OAM
Oxford Asset Management
United Kingdom
+$50.4K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$134K
2
Citigroup
Citigroup
New York
-$115K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$101K
4
ARTA
A.R.T. Advisors
New York
-$41K
5
CS
Credit Suisse
Switzerland
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$562K +$294K +321 +106%
BlackRock
2
BlackRock
New York
$290K +$295K +322 +32,200%
Renaissance Technologies
3
Renaissance Technologies
New York
$206K +$124K +135 +145%
Bank of New York Mellon
4
Bank of New York Mellon
New York
$69K +$70.5K +77 New
OAM
5
Oxford Asset Management
United Kingdom
$50K +$50.4K +55 New
Citadel Advisors
6
Citadel Advisors
Florida
$37K +$38.5K +42 New
VF
7
Virtu Financial
New York
$35K +$35.7K +39 New
EGM
8
Engineers Gate Manager
New York
$28K +$28.4K +31 New
Wells Fargo
9
Wells Fargo
California
$2K +$2.75K +3 New
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2 – – –
FP
11
Financial Perspectives
Minnesota
$2 – – –
AFM
12
Anson Funds Management
Texas
– -$428 -333 Closed
CH
13
CVI Holdings
Delaware
– -$134K -104 Closed
Citigroup
14
Citigroup
New York
– -$115K -90 Closed
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$101K -78 Closed
ARTA
16
A.R.T. Advisors
New York
– -$41K -32 Closed
CS
17
Credit Suisse
Switzerland
– -$38K -30 Closed
Bank of America
18
Bank of America
North Carolina
– -$916 -1 Closed
QT
19
Quantamental Technologies
New York
– -$1K -1 Closed

PSTV Hedge Fund Activity: Q4 2019 in Review

9 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2019, worth a combined $1.28M — up 36% from $941K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PSTV and 6 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was BlackRock, adding an estimated $295K. The largest seller was CVI Holdings, exiting entirely with an estimated $134K sold.

  • 9 institutional investors held Plus Therapeutics (PSTV) as of Q4 2019, down from 11 in Q3 2019.
  • Funds reported $1.28M of Plus Therapeutics stock for Q4 2019, up 36% quarter-over-quarter.
  • 6 funds opened new Plus Therapeutics positions in Q4 2019 and 8 closed out, a net change of -2 holders.
  • The largest Plus Therapeutics buyer in Q4 2019 was BlackRock, an estimated $295K added.
  • The largest Plus Therapeutics seller in Q4 2019 was CVI Holdings, an estimated $134K sold.

Based on aggregated 13F filings for Q4 2019.